The latest Partnership in Drug Delivery conference will kick off in Boston next week chaired by Roche Global Business Development Director Barbara Lueckel and with keynote speaker Robert Langer, MIT professor and biotech entrepreneur. FierceDrugDelivery will be on the scene and reporting next week with all the highlights.
A team from the Singapore-based Agency for Science, Technology and Research has found that a component of green tea has the potential to act as a nano-sized drug delivery vehicle to encapsulate proteins used to fight cancer.
Researchers at the Okinawa Institute of Science and Technology in Japan have developed what they call a nanosheet that is capable of holding drugs and is also reproducible for a number of different treatments.
MonoSol Rx announced that the U.S. Patent and Trademark Office will decide by August 2015 whether BioDelivery Sciences International's BEMA drug delivery technology infringes on a patent protecting its Suboxone sublingual film.
Pending FDA approval, the upgraded Prometra Implantable Pump System for targeted drug delivery of pain medication will feature MRI compatibility, Flowonix CEO Steve Adler told FierceDrugDelivery in an interview.
RNAi specialist Alnylam is focusing on rare diseases at the moment (with the exception of hepatitis B), but Chief Business Officer Laurence Reid told investors at the Leerink Rare Disease Roundtable conference that the company is also looking to enter bigger markets via partnerships.
Transparency Market Research predicts that the worldwide implantable drug delivery market will reach $21.1 billion by 2018.
A pill coated with tiny needles may help improve oral treatments, according to researchers. When swallowed, the pill delivers large molecules such as insulin into the lining of the stomach and does so more efficiently than an injection under the skin.
Finding the right delivery vehicle for a drug, one that will let the drug reach its full potential, is an invaluable prospect. And now MIT engineers have developed a way to test these vehicles quickly in vivo to determine which of them will be most efficient in delivering its payload.
RNAi leader Alnylam, the American Porphyria Consortium and The European Porphyria Network are launching the Explore observational study of patients with the rare disease, with the hope of advancing Alnylam's candidate for porphyria, with a goal of filing for approval in late 2014 or early 2015.
Allergan announced that the FDA has approved the company's Ozurdex sustained-release biodegradable implant to treat diabetic macular edema (DME). The expanded indication means the therapy, based on a proprietary delivery system, is approved for use in the general DME population, not just those with an artificial lens implant or in need of cataract surgery.
MIT scientists have employed a harmless version of the anthrax causing bacteria for drug delivery purposes, using it to insert drugs known as antibody mimics inside cells in the fight against cancer.
Last week the FDA cracked down hard on low-T therapies. Its expert panel voted to advise the agency to restrict the use of such drugs for a specific medical need.
Eye drug delivery outfit Novaliq touted a positive Phase I for its cyclosporin eye drops designed to treat dry eye disease. Novaliq's semifluorinated alkane technology allows for a clear solution of cyclosporin, which is poorly soluble in water, thus making for a more effective eye drop that doesn't impair vision, the company says.
After two false starts in the summer, drug delivery company Microlin Bio is once again withdrawing its planned IPO due to unfavorable market conditions. It had hoped to raise $28 million by offering 5.1 million shares on the Nasdaq priced between $4.50 and $5.50, Renaissance Capital reports.
A Purdue University team has created a new chip that promises to help test how cancer-killing nanoparticles react in a tumor environment. Because different nanoparticles perform vastly different functions in drug delivery, it's important to determine early on what kind of effect they will have on a tumor and what it would take to improve their outcome.
Titan Pharmaceuticals said yesterday that the Phase III study of its Probuphine subdermal implant for the treatment of opioid dependence is now halfway to full enrollment and on track to conclude by mid-2015, giving the company a second crack at FDA approval.
Researchers at Queen Mary University of London have developed antibodies that enable targeted drug delivery to arthritic cartilage, offering relief from rheumatoid arthritis.
Researchers at the University of Maryland at Baltimore succeeded in delivering nanoparticles into cancer cells that changed packaged DNA into circular DNA, a breakthrough that may have applications for oncology and gene-based therapy.
Australian nanopatch developer Vaxxas signed on with the World Health Organization this week in an effort to co-opt the company's patch for use with the polio vaccine. The WHO will help fund the research and move it through preclinical and clinical studies as the organization seeks to make polio a thing of the past.